For media inquiries, please contact:
Stephanie Dunn, Manager, Research Communications | 604-875-2401

Click on a tag to sort the news stories by theme:

New treatment more than doubles survival for high risk type of childhood leukemia

October 05, 2009
Share this:

Results of a phase two clinical trial led by Dr. Kirk Schultz show that adding continuous daily doses of a targeted drug called imatinib mesylate to regular chemotherapy more than doubled three-year survival rates for children with a high risk type of blood cancer called Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). [more...]

[Vancouver Sun story] [ story] [UPI story]